8-K filing — Altimmune, Inc. (ALT)
Filed: 2026-08-12 AccNo: 0001326190-26-000049 Size: 356 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
Altimmune Says Topline Data From RECLAIM Phase 2 Trial Of Pemvidutide For Alcohol Use Disorder Met Its Primary Endpoint Showing Statistically Significant Reduction In Heavy Drinking Days Vs. Placebo
Pemvidutide 2.4 mg delivered a statistically significant and clinically meaningful reduction in heavy drinking days, the primary endpoint of the trial Important secondary endpoints were also met, including two-level
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 28, 2026, 11:05 AM
- Checked
- Jul 28, 2026, 11:05 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Altimmune Q2 EPS $(0.12) Beats $(0.15) Estimate
Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 20 percent. This is a 55.56 percent increase over losses of $(0.27) per share from the same
Read original at benzingaAltimmune Announces Patient Enrollment Begins In PERFORMA Phase 3 Trial Of Pemvidutide In MASH, Enrolling About 1,790 Patients Across Two Cohorts, 52-Week Data Expected In 2029
Read original at benzingaAltimmune Says Lead Drug Shows Significant Alcohol Reduction in Mid-Stage Study
Altimmune reports positive Phase 2 RECLAIM trial data for pemvidutide in AUD and plans to request an EOP2 meeting with the FDA.
Read original at benzinga